US FDA clears Nitiloop’s device to treat chronic total occlusion

Nitiloop’s NovaCross CTO Microcatheter is designed for the treatment of chronic total occlusion prior to PTCA or stent intervention. Credit: Lenore Edman.



  • Nitiloop